Hot News
RNS: Drugs Controller General of India (DCGI), India’s drug regulator on Tuesday approved the emergency use of two Covid-19 vaccines, Biological E’s Corbevax and Bharat Biotech’s Covaxin, for children, aged …
Coronavirus vaccines for children aged between 5-12 years Read More
RNS: The prices of Covid vaccine, COVISHIELD (Serum Institute) and COVAXIN (Bharat Biotech) have been slashed for private hospitals. The price of the Covishield vaccine has been reduced from 600 …
Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals Read More
RNS: The subject expert committee (SEC) of Drugs controller General of India (DCGI) has recommended that Hyderabad-based Bharat Biotech can conduct phase- three trials on its intranasal vaccine. The company …
DGCI gives nod for Phase 3 trials of intranasal vaccine Read More
JNS: Amid India is facing the threat of Omicron, the latest variant of SARS-CoV-2, which is spreading very fast in the country, ‘Covaxin’ (Bharat Biotech), COVID-19 vaccine has received approval …
Covaxin gets nod for emergency use in children from 12 to 18 years of age Read More RNS: World Health Organisation (WHO) granted approval to India’s first indigenous COVID-19 vaccine– Covaxin– for emergency use listing (EUL) for COVID-19 on Wednesday. The Technical Advisory Group of WHO, which …
WHO grants approval to Covaxin for emergency use Read More
RNS: Covovax, another COVID-19 vaccine, being manufactured by Serum Institute of India, will be launched in October for adults and for children by the first quarter of 2022, said Adar …
COVID jab for kids by first quarter of 2022: Poonawalla Read More
#Bharat Biotech applies for WHO emergency use listing for Covaxin RSN: Rejecting the claims and media reports that “Vaccine Passport”— that the type of vaccine administered— will regulate international travel, …
“Vaccine Passport”: No consensus yet at WHO level Read More RNS: The Central Government is mulling to increase the production of indigenously developed Covaxin— COVID-19 vaccine to approximately 1 million doses per month. Presently Bharat Biotech’s Covaxin production capacity is …
India to ramp up Covaxin production under Atmanirbhar Bharat 3.0 Read More
RNS: The government has increased the intervals between two doses of Covishield to 12 to 16 weeks from the existing 6 to 8 weeks on Thursday. This is the second …
Covishield 2nd dose interval increases to 12-16 weeks Read More RNS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, official sources said. The trial …
Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds Read More